Journal of Leukemia
Open Access
ISSN: 2329-6917
ISSN: 2329-6917
Lindsey N Kissinger
Tanzania
Research Article
Therapeutic Combination of Nanoliposomal Safingol and Nanoliposomal Ceramide for Acute Myeloid Leukemia
Author(s): Timothy J Brown, Aileen M. Garcia, Lindsey N Kissinger, Sriram S Shanmugavelandy, Xujung Wang, Myles C Cabot, Mark Kester, David F Claxton and Brian M BarthTimothy J Brown, Aileen M. Garcia, Lindsey N Kissinger, Sriram S Shanmugavelandy, Xujung Wang, Myles C Cabot, Mark Kester, David F Claxton and Brian M Barth
Novel approaches to enhancing the efficacy of ceramide-based therapeutics are of interest for the treatment of acute myeloid leukemia (AML). Ceramide is a bioactive sphingolipid that has long been established as an inducer of apoptosis. We have pioneered the effort to develop nanoliposomal C6-ceramide (Lip-C6) as an anticancer therapeutic and recently have engaged in efforts to enhance its therapeutic efficacy. Ceramide catabolism by acid ceramidase and subsequently sphingosine kinase 1 yields the metabolite oncogenic sphingosine-1-phosphate (S1P). Therefore, in the present study we hypothesized that targeting of this metabolic pathway with the sphingosine kinase 1 inhibitor safingol would augment the anti-AML efficacy of Lip-C6. We generated and evaluated nanoliposomes encapsulating safingol (Lip-Saf), in combination with Lip-C6 using AML cell lines and primary AML patient samples. This.. Read More»
DOI:
10.4172/2329-6917.1000110
